Biotechnology Update
- 1 March 1999
- journal article
- Published by Elsevier in Journal of the American Pharmaceutical Association
- Vol. 39 (2), 236-238
- https://doi.org/10.1016/s1086-5802(16)30498-3
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Herceptin raises its sights beyond advanced breast cancer.JNCI Journal of the National Cancer Institute, 1998
- HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.Journal of Clinical Oncology, 1997
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989